Johnson & Johnson Opens First Satellite Center for Global Health Discovery in Asia Pacific at Duke-NUS to Advance Dengue Research
SINGAPORE, June 21, 2022 – Johnson & Johnson (the Company) today announced the launch of the new J&J Satellite Center for Global Health Discovery (Satellite Center) at Singapore’s Duke-NUS Medical School, jointly established by Duke University and the National University of Singapore (NUS) as a graduate-entry medical school and research powerhouse. As the first of the J&J Centers for Global Health Discovery (J&J Centers) in the Asia-Pacific region, the Satellite Center at Duke-NUS aims to help drive new solutions to address flaviviruses, which disproportionately impact communities across the region, by ...
Source: Johnson and Johnson - June 21, 2022 Category: Pharmaceuticals Source Type: news

Analyzing the Cost of Hospital Contact Isolation Practices: Implications for Nursing Administrator Practice, Research, and Policy
This study aimed to determine the weekly costs of contact precaution (CP) use with medically stable patients infected/colonized with methicillin-resistant Staphylococcus aureus (MRSA) and to estimate the annual financial and environmental costs of CP. Background: The increasing use of disposables for infection control contributes to increasing hospital costs and amounts of solid waste at rates that are becoming unsustainable. Methods: A cost analysis was conducted using data from time/motion observations and previous waste audit study, along with hospital finance department values and US Department of Labor salary rates. R...
Source: Current Awareness Service for Health (CASH) - June 17, 2022 Category: Consumer Health News Source Type: news

Laboratory-identified vancomycin-resistant enterococci bacteremia incidence: A standardized infection ratio prediction model.
We analyzed 2017 healthcare facility-onset (HO) vancomycin-resistant Enterococcus (VRE) bacteremia data to identify hospital-level factors that were significant predictors of HO-VRE using the Centers for Disease Control and Prevention (CDC) National Healthcare Safety Network (NHSN) multidrug-resistant organism and Clostridioides difficile reporting module. A risk-adjusted model that can be used to calculate the number of predicted HO-VRE bacteremia events in a facility was developed, thus enabling the calculation of VRE standardized infection ratios (SIRs). Methods: Acute-care hospitals reporting at least 1 month of 2017 ...
Source: Current Awareness Service for Health (CASH) - June 16, 2022 Category: Consumer Health News Source Type: news

Multidrug-Resistant Bloodstream Infections in Internal Medicine Multidrug-Resistant Bloodstream Infections in Internal Medicine
This study analyzed trends of multidrug-resistant organism bacteremia and antimicrobial resistance rates in the complex setting of an Internal Medicine ward.Southern Medical Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 6, 2022 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

Increasing usage of chlorhexidine in health care settings: blessing or curse? A narrative review of the risk of chlorhexidine resistance and the implications for infection prevention and control
This study reviewed the published data regarding the evidence of reduced CHG susceptibility, the cross-resistance with antibiotics, and the implications for infection control for S. aureus, coagulase-negative staphylococci, E. coli, K. pneumoniae, and P. aeruginosa. Despite incongruity in definitions of " resistance, " 12 increased CHG minimal inhibitory values of these pathogens have been described, and different mutations encoding for CHG efflux pumps have been identified. Clinical relevance of species with reduced susceptibility to CHG is debatable and cross-resistance with antibiotics remains controversial. However, so...
Source: Current Awareness Service for Health (CASH) - May 17, 2022 Category: Consumer Health News Source Type: news

Support for Gilead Drug's Benefit Against Multidrug-Resistant HIV Support for Gilead Drug's Benefit Against Multidrug-Resistant HIV
Lenacapavir produces higher levels of viral suppression after 26 weeks among patients with multidrug-resistant disease when given in addition to other antiretrovirals, according to results from the CAPELLA trial.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - May 12, 2022 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Lenacapavir Reduces Viral Load in Multidrug-Resistant HIV-1 Infection
THURSDAY, May 12, 2022 -- Patients with multidrug-resistant HIV-1 infection receiving the capsid inhibitor lenacapavir have a greater reduction in viral load than those receiving placebo, according to a study published in the May 12 issue of the New... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 12, 2022 Category: Pharmaceuticals Source Type: news

Africa: WHO Issues Rapid Communication On Updated Guidance for the Treatment of Drug-Resistant Tuberculosis
[WHO] A rapid communication released by the World Health Organization (WHO) Global Tuberculosis Programme has announced upcoming updates to the guidance on the treatment of drug-resistant tuberculosis (DR-TB). These updates include shorter novel 6-month all-oral regimens for the treatment of multidrug- and rifampicin-resistant TB (MDR/RR-TB), with or without additional resistance to fluoroquinolones (pre-XDR-TB) as well as an alternative 9-month all-oral regimen for the treatment of MDR/RR-TB. (Source: AllAfrica News: Tuberculosis)
Source: AllAfrica News: Tuberculosis - May 9, 2022 Category: Infectious Diseases Source Type: news

Africa: Drug-Resistant Tuberculosis Trial Results in Updated Treatment Guidelines
[MSF] Geneva -- The World Health Organization (WHO) has announced it will update global guidance on treatment of multidrug-resistant tuberculosis (MDR-TB), following the results shared from the TB PRACTECAL trial. The clinical trial from M édecins Sans Frontières (MSF) has found a new, safer and more effective six-month oral treatment regimen for MDR-TB. (Source: AllAfrica News: Tuberculosis)
Source: AllAfrica News: Tuberculosis - May 6, 2022 Category: Infectious Diseases Source Type: news

Global rollout of rapid molecular tests for tuberculosis over the last 12 years: Cochrane Review summarizes research on recipient and provider views
A potential game-changer in the tuberculosis epidemic was how the tuberculosis community viewed rapid molecular tests for tuberculosis and tuberculosis drug resistance. This was 12 years ago, with the launch of Xpert MTB/RIF, which gives results in less than two hours, simultaneously diagnosing tuberculosis and testing if the bacteria have rifampicin resistance, a type of drug-resistant tuberculosis. Multidrug-resistant tuberculosis is caused by resistance to at least both rifampicin and isoniazid, the two most effective first-line drugs used to treat tuberculosis.  Yet, diagnostic tests only have an impact on health if t...
Source: Cochrane News and Events - May 2, 2022 Category: Information Technology Authors: Muriah Umoquit Source Type: news

Johnson & Johnson Launches Next Satellite Center for Global Health Discovery at Holistic Drug Discovery and Development Centre, University of Cape Town, Focused on Antimicrobial Resistance (AMR)
Cape Town, South Africa, April 25, 2022 – Johnson & Johnson (the Company) today announced the launch of the J&J Satellite Center for Global Health Discovery (Satellite Center) at the Holistic Drug Discovery and Development (H3D) Centre, University of Cape Town, in Cape Town, South Africa. This marks the latest expansion of the J&J Centers for Global Health Discovery (J&J Centers), a global network of research collaborations between the Company and leading research institutions to accelerate translational and discovery research to address some of the world’s most pressing global health challenges. The Sa...
Source: Johnson and Johnson - April 25, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Cleaning and disinfecting surfaces in hospitals and long-term care facilities for reducing hospital- and facility-acquired bacterial and viral infections: a systematic review
Conclusion: Ten c-RCTs focused on reducing multiple MDROs and/or HAIs and four had significant reductions. Three c-RCTs reported only patient MRSA colonization rates (o ne significant reductions), and one focused on C. difficile (no significant differences). Standardized primary and secondary outcomes are required for future c-RCTs including detailed biofilm cleaning/disinfection interventions. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 21, 2022 Category: Consumer Health News Source Type: news

An easy-to-use antimicrobial hydrogel effectively kills bacteria, fungi, and influenza virus
Various drug resistant pathogens such as bacteria, fungi and viruses enter a host through different routes, which can lead to health-related problems and even fatalities. Propagation of these infectious microbes majorly occurs through the mucosal openings or upon topical contact. To curb their transmission or to cure infections associated with these pathogens, herein we describe the development of an antimicrobial hydrogel, based on a water soluble quaternary lipophilic polyethyleneimine derivative (QPEINH-C6). The cationic polymer QPEINH-C6 exhibited antibacterial activity against drug-resistant Gram-positive bacteria (MI...
Source: Current Awareness Service for Health (CASH) - April 21, 2022 Category: Consumer Health News Source Type: news

Johnson & Johnson Announces Series of Youth Initiatives Aimed at Helping to Empower a Generation to End Tuberculosis
NEW BRUNSWICK, N.J., March 24, 2022 – Today on World Tuberculosis (TB) Day, Johnson & Johnson (the Company) announced a series of initiatives in high TB burden countries aimed at helping to empower a generation of youth to end TB. The initiatives focus on supporting global efforts to help find the missing millions of people living with undiagnosed TB, and are part of Johnson & Johnson’s 10-year initiative to help drive progress toward the United Nations (UN) Sustainable Development Goal of ending this deadly, but preventable and treatable, disease by 2030.Johnson & Johnson, together with the Central TB Divi...
Source: Johnson and Johnson - March 24, 2022 Category: Pharmaceuticals Source Type: news

Increasing usage of chlorhexidine in health care settings: blessing or curse? A narrative review of the risk of chlorhexidine resistance and the implications for infection prevention and control
This study reviewed the published data regarding the evidence of reduced CHG susceptibility, the cross-resistance with antibiotics, and the implications for infection control for S. aureus, coagulase-negative staphylococci, E. coli, K. pneumoniae, and P. aeruginosa. Despite incongruity in definitions of " resistance, " increased CHG minimal inhibitory values of these pathogens have been described, and different mutations encoding for CHG efflux pumps have been identified. Clinical relevance of species with reduced susceptibility to CHG is debatable and cross-resistance with antibiotics remains controversial. However, some ...
Source: Current Awareness Service for Health (CASH) - March 21, 2022 Category: Consumer Health News Source Type: news